LPTX News and Press, Leap Therapeutics Inc. From 06/17/20

CAMBRIDGE, Mass. , June 17, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of c...

Yunhong CTI (NASDAQ: CTIB ) +304% . More news on: Yunhong CTI Ltd., KBS Fashion Group Limited, ZK International Group Co., Ltd., Stocks on the move, , Read more ...

The FDA has designated Leap Therapeutics' (NASDAQ: LPTX ) Phase 1/2-stage DKN-01, a humanized monoclonal antibody that blocks the activity of the Dickkopt-1 (DKK1) protein, an Orphan Drug for the treatment of gastric and gastroesophageal junction cancer. More news on: Leap Therapeutics, ...

CAMBRIDGE, Mass. , June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation...

CAMBRIDGE, Mass. , June 11, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, due to public health and safety concerns related to the outbreak of the novel coronavirus...

Leap Therapeutics (NASDAQ: LPTX ): Q1 GAAP EPS of -$0.55 misses by $0.31 . More news on: Leap Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CAMBRIDGE, Mass. , April 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its anti-Dickkop...

Leap Therapeutics (NASDAQ: LPTX ) announces changes to the Executive Leadership Team, effective immediately. Other management changes will take effect April 1. More news on: Leap Therapeutics, Inc., Healthcare stocks news, Read more ...

CAMBRIDGE, Mass. , March 18, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced changes to the Company's Executive Leadership Team. All changes to the Board of Direct...

Leap Therapeutics (NASDAQ: LPTX ): Q4 GAAP EPS of -$0.33 misses by $0.01 . More news on: Leap Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...